Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update

CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline, clomipramine, doxepin, imipramine, and trimi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Pharmacol Ther
Huvudupphovsmän: Hicks, J. Kevin, Sangkuhl, Katrin, Swen, Jesse J., Ellingrod, Vicki L., Müller, Daniel J., Shimoda, Kazutaka, Bishop, Jeffrey R., Kharasch, Evan D., Skaar, Todd C., Gaedigk, Andrea, Dunnenberger, Henry M., Klein, Teri E., Caudle, Kelly E., Stingl, Julia C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2017
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5478479/
https://ncbi.nlm.nih.gov/pubmed/27997040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.597
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk